MCK · Consumer

MCKESSON CORP

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

• Operating Income and MarginsImportance 47 · Surprise 48
  Fiscal Q1 2027 gross profit was reported at approximately $3.7 billion. Adjusted EPS rose 20% year over year to $9.93, while some coverage reported lower net income and diluted EPS on a GAAP basis despite higher sales.…

News · 2026-08-07

• Medical-Surgical SeparationImportance 58 · Surprise 68
  McKesson Medical-Surgical Solutions is being separated into an independent business named Wellverse, with formal operation under the new name planned for January 2027. The business had fiscal Q1 2027 revenue of $2.8…
• Capital Return ProgramImportance 52 · Surprise 42
  McKesson announced a plan to repurchase up to $5 billion of its shares. The company also increased its quarterly dividend, although the reported coverage did not specify the new per-share amount. Buybacks were…

News · 2026-08-06

• Medical-Surgical SeparationImportance 58 · Surprise 68
  McKesson Medical-Surgical Solutions is being separated into an independent business named Wellverse, with formal operation under the new name planned for January 2027. The business had fiscal Q1 2027 revenue of $2.8…
• Acquisition / Partnership / DivestitureImportance 58 · Surprise 68
  McKesson is separating its Medical-Surgical Solutions business, which will be rebranded Wellverse in January 2027. Wellverse is expected to become an independent, publicly traded company through a potential IPO in the…
• Capital Return ProgramImportance 52 · Surprise 42
  McKesson announced a plan to repurchase up to $5 billion of its shares. The company also increased its quarterly dividend, although the reported coverage did not specify the new per-share amount. Buybacks were…
• Operating Income and MarginsImportance 47 · Surprise 48
  Fiscal Q1 2027 gross profit was reported at approximately $3.7 billion. Adjusted EPS rose 20% year over year to $9.93, while some coverage reported lower net income and diluted EPS on a GAAP basis despite higher sales.…
• Pharma Profit GrowthImportance 42 · Surprise 40
  McKesson's pharma profit increased 19% in fiscal Q1 2027, exceeding the 10% year-over-year materiality threshold. Oncology and specialty-drug demand were identified as the primary drivers of the profit increase. Higher…
• Headcount and RestructuringImportance 31 · Surprise 42
  Rx Savings Solutions, a McKesson-owned prescription price-transparency company in Overland Park, announced layoffs to streamline operations and focus on growth. The number of affected employees was not disclosed, and…
• Pharmaceutical Distribution CompetitionImportance 10 · Surprise 6
  McKesson operates in a concentrated U.S. pharmaceutical distribution market alongside Cardinal Health and Cencora. The three leading wholesalers collectively control more than 90% of U.S. drug distribution, indicating…

10-Q · 2026-08-05

• Liquidity and Debt PositionImportance 84 · Surprise 74
  Cash and cash equivalents increased to $5.164 billion at June 30, 2026, from $3.975 billion at March 31, 2026, while total assets increased to $88.330 billion from $82.323 billion. Total debt increased to $9.729…
• Oncology Specialty DemandImportance 70 · Surprise 56
  Oncology & Multispecialty revenue increased 33% year over year to $14,222 million from $10,658 million in the three months ended June 30, 2026. The segment serves specialty-care markets through specialty drug…
• FX / Currency ImpactImportance 68 · Surprise 58
  McKesson operates in U.S. dollars and the functional currencies of foreign subsidiaries, including Canadian dollars, euros, and British pounds sterling, creating translation and intercompany-loan exposure. In July…
• Opioid LitigationImportance 65 · Surprise 60
  McKesson and two other national pharmaceutical distributors entered a $7.9 billion settlement with participating U.S. states, subdivisions, the District of Columbia, and eligible territories, with payments extending…
• Medical-Surgical SeparationImportance 53 · Surprise 60
  On June 1, 2026, Apollo Global Management affiliates invested approximately $1.25 billion in convertible preferred equity of Medical-Surgical Solutions for an approximately minority ownership interest classified as…
• Debt Financing and LiquidityImportance 52 · Surprise 42
  In the first quarter of fiscal 2027, subsidiaries in the Medical-Surgical Solutions segment entered into syndicated financing totaling $3.2 billion of net proceeds. The financing includes $750 million of senior secured…
• Capital Return ProgramImportance 46 · Surprise 42
  McKesson returned $2.6 billion of cash to shareholders during the three months ended June 30, 2026. Common-stock repurchases totaled $2.5 billion, including a $2.3 billion March accelerated share repurchase completed…
• Headcount and RestructuringImportance 40 · Surprise 42
  During the first quarter of fiscal 2027, McKesson approved multi-year Corporate initiatives involving organizational changes, process enhancements, and automation solutions to improve efficiency and productivity. The…
• Regulatory RiskImportance 38 · Surprise 24
  McKesson files tax returns in U.S. federal, U.S. state, and foreign jurisdictions and had $1.6 billion of unrecognized tax benefits as of June 30, 2026. Of that amount, $1.5 billion would reduce income tax expense and…
• Operational Efficiency InitiativesImportance 37 · Surprise 42
  McKesson’s Prescription Technology Solutions segment launched an operational-efficiency and cost-optimization initiative to align the business with its long-term strategy. The actions include headcount reductions,…
• Market Demand TrendsImportance 37 · Surprise 32
  McKesson reported broad market growth in the three months ended June 30, 2026, led by North American Pharmaceutical demand. Growth reflected higher drug utilization, newly launched products, and higher volumes from…
• Pharmaceutical Distribution VolumesImportance 37 · Surprise 32
  North American Pharmaceutical revenue increased $4.0 billion, or 5%, year over year to $86.8 billion. Higher volumes from institutional healthcare providers and retail national account customers were the principal…
• Net Income and ProfitabilityImportance 35 · Surprise 48
  Net income attributable to McKesson declined 22% to $614 million from $784 million for the three months ended June 30, 2026. Diluted earnings per share decreased 18% to $5.15 from $6.25, despite diluted…
• Income Tax Rate ChangesImportance 35 · Surprise 48
  Income tax expense increased to $276 million from $220 million for the three months ended June 30, 2026. The reported income tax rate increased to 21.1% from 20.9%, a 20-basis-point increase. The rate change was driven…
• Revenue Performance and MixImportance 34 · Surprise 32
  Total revenue increased 8% year over year to $105.38 billion from $97.83 billion for the three months ended June 30, 2026. North American Pharmaceutical revenue rose 5% to $86.77 billion, with U.S. sales increasing…
• Geographic Market CommentaryImportance 32 · Surprise 24
  The U.S. was the primary geographic source of North American Pharmaceutical growth. U.S. sales increased $3.7 billion, driven primarily by higher volumes from institutional healthcare providers and retail national…
• Recent Accounting PronouncementsImportance 25 · Surprise 42
  The FASB issued ASU 2024-03, requiring interim and annual disaggregation of certain income-statement costs and expenses; it becomes effective for McKesson fiscal years beginning after December 15, 2026, with interim…
• Healthcare Customer GrowthImportance 25 · Surprise 32
  Medical-Surgical Solutions revenue increased $118 million, or 4%, year over year to $2.8 billion. Sales to extended care customers rose $79 million, while sales to ambulatory care customers rose $35 million. Both…
• Operating Expense TrendsImportance 24 · Surprise 14
  Selling, distribution, general, and administrative expenses increased 3.1% year over year to $2.264 billion for the quarter ended June 30, 2026, from $2.196 billion. Total operating expenses increased 5.5% to $2.366…
• Capital ExpendituresImportance 23 · Surprise 22
  Capital expenditures for property, plant, and equipment and capitalized software were $152 million for the three months ended June 30, 2026. Capital expenditures decreased from $189 million in the prior-year period.…
• Gross Margin DriversImportance 20 · Surprise 40
  Gross profit increased to $3.685 billion for the three months ended June 30, 2026 from $3.279 billion in the prior-year period. Gross margin expanded to 3.50% from 3.35%, an improvement of 15 basis points. The increase…
• Products and TechnologyImportance 10 · Surprise 6
  McKesson provides branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical distribution and logistics, along with financial, operational, clinical, consulting, outsourcing, and technology solutions…
• Distribution ChannelsImportance 10 · Surprise 6
  McKesson distributes pharmaceuticals and healthcare products through logistics services serving retail, hospital, and alternate-site pharmacies in the U.S. and Canada. Oncology & Multispecialty includes…

8-K · 2026-08-05

• Guidance / OutlookImportance 79 · Surprise 76
  McKesson raised fiscal 2027 adjusted earnings per diluted share guidance to $44.20-$45.00 from $43.80-$44.60. The updated range implies 13%-15% growth versus the prior year and reflects strong first-quarter performance…
• Liquidity and Debt PositionImportance 77 · Surprise 82
  Cash and cash equivalents increased to $5.164 billion at June 30, 2026 from $3.975 billion at March 31, 2026. Long-term debt rose to $8.432 billion from $5.259 billion, and current debt was $1.297 billion, reflecting…
• Specialty Distribution GrowthImportance 64 · Surprise 56
  The North American Pharmaceutical segment reported $86.8 billion of revenue, up 5% year over year, driven by increased prescription transaction volumes and higher specialty-product volumes. Growth in specialty…
• Acquisition / Partnership / DivestitureImportance 53 · Surprise 60
  McKesson sold Apollo Funds an approximately 13% minority interest in Medical-Surgical Solutions for $1.25 billion on June 1, 2026. The transaction generated a $293 million redemption-value adjustment for redeemable…
• Operating Expense TrendsImportance 45 · Surprise 50
  GAAP selling, distribution, general, and administrative expense increased 3% year over year to $2.264 billion from $2.196 billion. Total operating expenses increased 5% to $2.366 billion, including $136 million of…
• Net Income and EPS PerformanceImportance 43 · Surprise 66
  GAAP net income attributable to McKesson fell 22% year over year to $614 million from $784 million, and diluted EPS declined 18% to $5.15 from $6.25. The decline primarily reflected a $293 million redemption-value…
• Market Demand TrendsImportance 43 · Surprise 32
  McKesson’s first-quarter revenues increased 8% to $105.4 billion, driven by higher prescription transaction volumes and distribution of specialty products in the North American Pharmaceutical segment. North American…
• Operating Margin DriversImportance 41 · Surprise 48
  GAAP operating income increased 27% year over year to $1.319 billion from $1.036 billion, while gross profit rose 12% to $3.685 billion. Adjusted segment operating profit increased 19% in North American Pharmaceutical…
• Revenue Performance and MixImportance 36 · Surprise 14
  First-quarter fiscal 2027 revenue increased 8% year over year to $105.4 billion from $97.8 billion. North American Pharmaceutical revenue rose 5% to $86.8 billion, driven by higher prescription transaction volumes and…
• Capital Return ProgramImportance 32 · Surprise 24
  McKesson returned $2.6 billion to shareholders during the quarter, consisting of $2.5 billion of common-stock repurchases and $102 million of dividend payments. The company completed a $2.25 billion accelerated share…
• Prescription Technology DemandImportance 31 · Surprise 32
  Prescription Technology Solutions revenue rose 9% to $1.6 billion in the quarter. Demand was driven by increased prescription volumes in third-party logistics and access solutions. McKesson reported that higher demand…
• Income Tax Rate ChangesImportance 24 · Surprise 30
  GAAP income tax expense increased 25% year over year to $276 million from $220 million. The increase accompanied a 24% rise in income before taxes to $1.308 billion from $1.051 billion. Adjusted income tax expense…

News · 2026-08-05

• Guidance and OutlookImportance 51 · Surprise 60
  McKesson raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00 per share from its prior forecast. The new range was above the FactSet estimate of $44.26 per share. The guidance increase followed fiscal Q1 adjusted…
• Guidance / OutlookImportance 51 · Surprise 60
  McKesson raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00, above its prior outlook and the $44.26 FactSet estimate. Management attributed the increase to strong oncology and specialty-drug performance,…
• Operating Income and MarginsImportance 47 · Surprise 48
  Fiscal Q1 2027 gross profit was reported at approximately $3.7 billion. Adjusted EPS rose 20% year over year to $9.93, while some coverage reported lower net income and diluted EPS on a GAAP basis despite higher sales.…
• Revenue Performance and MixImportance 34 · Surprise 32
  McKesson reported fiscal Q1 2027 revenue of $105.38 billion, up 7.7% year over year and ahead of consensus estimates by 0.95%. Growth was driven by the U.S. Pharmaceutical business, oncology services and specialty…
• Specialty Drug Demand GrowthImportance 20 · Surprise 24
  Demand for specialty medicines remained strong, with increased prescription volumes supporting McKesson’s oncology and specialty drug businesses. North American Pharmaceutical and Oncology were identified as key growth…

News · 2026-08-04

• Revenue Performance and MixImportance 34 · Surprise 32
  McKesson reported fiscal Q1 2027 revenue of $105.38 billion, up 7.7% year over year and ahead of consensus estimates by 0.95%. Growth was driven by the U.S. Pharmaceutical business, oncology services and specialty…
• Headcount and RestructuringImportance 31 · Surprise 42
  Rx Savings Solutions, a McKesson-owned prescription price-transparency company in Overland Park, announced layoffs to streamline operations and focus on growth. The number of affected employees was not disclosed, and…
• Specialty Drug Demand GrowthImportance 20 · Surprise 24
  Demand for specialty medicines remained strong, with increased prescription volumes supporting McKesson’s oncology and specialty drug businesses. North American Pharmaceutical and Oncology were identified as key growth…